A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
| Autor: | San Choon Kong, Brian John Schwender, Sai Wei Chuah, Hang Hock Shim, Pak Wo Webber Chan, Khoon Lin Ling |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty Hepatology business.industry Treatment outcome Gastroenterology Inflammatory Bowel Diseases medicine.disease Inflammatory bowel disease law.invention Vedolizumab 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law 030220 oncology & carcinogenesis Internal medicine Ustekinumab Medicine 030211 gastroenterology & hepatology Tumor necrosis factor alpha business Cohort study medicine.drug |
| Zdroj: | JGH Open. 2:223-234 |
| ISSN: | 2397-9070 |
| Popis: | Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much-awaited out-of-class alternatives for patients who have failed or who are intolerant to anti-Tumor Necrosis Factor (TNF) therapy. However, questions remain as to how we may best use these novel therapeutic agents. We evaluate the evidence available from randomized controlled trials and postmarketing cohort studies and discuss their safety, efficacy, and limitations, in relation to anti-TNF therapy, in optimizing the treatment outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text